Nama's AI scorecard currently rates uniQure Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does QURE report earnings?

uniQure's next scheduled report is on Mar 2, 2027. Analysts expect EPS of -$0.81.

What is the QURE price target?

The median analyst price target from 11 analysts is $63.92, with a range of $27.83 – $91.02.

Is QURE Shariah compliant?

Nama's AAOIFI-style screen reads uniQure as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

uniQure (QURE)

Healthcare · Biotechnology · NASDAQ

uniQure (QURE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.52B and a free-cash-flow yield of -14.3%. Over the most recent reported fiscal year, revenue declined 40.6%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -15.9% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-69.7%

How far the last close sits under the highest price of the past five years.

Market cap	$1.52B
Trailing P/E	—
Price / book	4.7
Price / sales	80.4
FCF yield	-14.3%
Dividend yield	—
Gross margin	92.5%
Operating margin	-1017.2%
Net margin	-1350.7%
Revenue growth (YoY)	-40.6%
Revenue growth (3-yr annual)	-46.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

QURE earnings

Next report: Mar 2, 2027 (Q4 2026, EPS estimate -$0.81). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.78	-$0.82	+4.9%	$5.20M
Q2 2026	Jul 29, 2026	-$1.07	-$0.71	-50.7%	$5.84M
Q1 2026	May 5, 2026	-$0.73	-$0.75	+2.7%	$3.56M
Q4 2025	Mar 2, 2026	-$0.47	-$0.78	+39.7%	$5.57M

QURE analyst price target

Median target $63.92 from 11 analysts, ranging $27.83 – $91.02.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live QURE data on Nama Insights →

QURE FAQ

Is QURE a buy?: Nama's AI scorecard currently rates uniQure Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does QURE report earnings?: uniQure's next scheduled report is on Mar 2, 2027. Analysts expect EPS of -$0.81.
What is the QURE price target?: The median analyst price target from 11 analysts is $63.92, with a range of $27.83 – $91.02.
Is QURE Shariah compliant?: Nama's AAOIFI-style screen reads uniQure as Not Shariah Compliant. At least one of the three ratios or the industry test failed.